San Francisco is making a comeback. So are these stocks from the City by the Bay

An analysis of San Francisco-based companies with market capitalizations over $500 million, excluding Silicon Valley, identified biotech firms as the surprising top performers over the last three months, rather than AI-related stocks. Nektar Therapeutics (NKTR) led the gains with a nearly 150% increase, driven by its dermatitis and alopecia treatments. Other notable performers included RealReal (REAL), Planet Labs (PL), and Sunrun (RUN), demonstrating strong investor interest across diverse sectors like resale, earth intelligence, and solar, despite some exhibiting significant past volatility.

Analysis

A recent analysis of San Francisco-headquartered companies with market capitalizations exceeding $500 million revealed a surprising dominance of biotech firms among top performers over the last three months, contrary to expectations of AI-related leadership. This screening, which excluded Silicon Valley, identified Nektar Therapeutics (NKTR) as the leading stock with a remarkable 158.65% gain. The general sentiment surrounding these findings is extremely positive, reflecting an optimistic outlook on the city's economic resurgence.

Nektar Therapeutics (NKTR) is developing treatments for dermatitis and alopecia, with analysts maintaining a bullish average price target of $93.60, indicating a potential 50% upside. Beyond biotech, other significant performers included RealReal (REAL) with a 121.42% increase in luxury resale, Planet Labs (PL) up 100.60% in 'earth intelligence,' and Sunrun (RUN) gaining 89.24% in solar power. This highlights a diverse range of sectors contributing to the region's strong market performance.

While these companies have shown substantial gains, some, like Sunrun (RUN) and Planet Labs (PL), have experienced considerable share price volatility, with both seeing significant drops and recoveries within the last year. RealReal (REAL) is currently trading slightly above its median analyst price target, warranting investor caution. The strong performance across these varied companies suggests renewed investor interest in fundamental growth stories and specific industry trends.

Key Decisions for Investors

• Investors should conduct thorough due diligence on top-performing San Francisco biotech firms, such as Nektar Therapeutics (NKTR), Maze Therapeutics (MAZE), and Olema Pharmaceuticals (OLMA), to assess the sustainability of their recent gains and pipeline potential.
• Given the noted volatility in stocks like Sunrun (RUN) and Planet Labs (PL), investors should evaluate risk-adjusted returns and consider entry points carefully, focusing on long-term fundamentals rather than short-term momentum.
• For companies like RealReal (REAL) trading above median analyst price targets, a cautious approach is warranted, with investors advised to scrutinize valuation metrics and future growth catalysts.
• Consider the broader implications of the San Francisco market's diverse sector strength, particularly the unexpected outperformance of biotech over AI, when formulating regional investment strategies.